Ixico Plc (IXI) New Ord GBP0.01

Sell:12.00pBuy:12.50pNo change

Prices delayed by at least 15 minutes
Sell:12.00p
Buy:12.50p
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:12.00p
Buy:12.50p
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.

Key people

Bram Goorden
Chief Executive Officer
Grant Robert Nash
Chief Financial Officer, Executive Director, Company Secretary
Mark Robert Warne
Non-Executive Chairman of the Board
Katherine Jane Rogers
Non-Executive Director
Dipti Amin
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    IXI
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BFXR4C20
  • Market cap
    £11.35m
  • Employees
    81
  • Shares in issue
    92.67m
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.